Cadrenal Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
The PNC Financial Services Group, Inc. has filed a Schedule 13G, reporting beneficial ownership of 8.13% of Cadrenal Therapeutics, Inc. common stock as of June 30, 2026.
NASDAQ
Three Czech Republic-based entities, Havlickova 648 a.s., Dubnica Property s.r.o., and Miroslav Dornak, have filed an amended Schedule 13G disclosing a collective beneficial ownership of 4.39% in Cadrenal Therapeutics, Inc.
NASDAQ
John Raymond Murphy, an insider at Cadrenal Therapeutics, Inc., has filed an amended Schedule 13G, disclosing beneficial ownership of 2.96% of the company's common stock as of December 31, 2024.